Jänicke F - Search Results

1

Comparison of microarray-based RNA expression with ELISA-based protein determination of HER2, uPA and PAI-1 in tumour tissue of patients with breast cancer and relation to outcome.

Witzel ID, Milde-Langosch K, Wirtz RM, Roth C, Ihnen M, Mahner S, Zu Eulenburg C, Jänicke F, Müller V. Witzel ID, et al. Among authors: janicke f. J Cancer Res Clin Oncol. 2010 Nov;136(11):1709-18. doi: 10.1007/s00432-010-0829-4. Epub 2010 Mar 4. J Cancer Res Clin Oncol. 2010. PMID: 20204407

2

Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients.

Foekens JA, Schmitt M, van Putten WL, Peters HA, Bontenbal M, Jänicke F, Klijn JG. Foekens JA, et al. Among authors: janicke f. Cancer Res. 1992 Nov 1;52(21):6101-5. Cancer Res. 1992. PMID: 1394237

3

Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2.

Schmalfeldt B, Kuhn W, Reuning U, Pache L, Dettmar P, Schmitt M, Jänicke F, Höfler H, Graeff H. Schmalfeldt B, et al. Among authors: janicke f. Cancer Res. 1995 Sep 15;55(18):3958-63. Cancer Res. 1995. PMID: 7664262

4

Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy.

Kuhn W, Pache L, Schmalfeldt B, Dettmar P, Schmitt M, Jänicke F, Graeff H. Kuhn W, et al. Among authors: janicke f. Gynecol Oncol. 1994 Dec;55(3 Pt 1):401-9. doi: 10.1006/gyno.1994.1313. Gynecol Oncol. 1994. PMID: 7835780

5

Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.

Jänicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A, Graeff H. Jänicke F, et al. Cancer Res. 1994 May 15;54(10):2527-30. Cancer Res. 1994. PMID: 8168072

6

Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer.

Schmitt M, Thomssen C, Ulm K, Seiderer A, Harbeck N, Höfler H, Jänicke F, Graeff H. Schmitt M, et al. Among authors: janicke f. Br J Cancer. 1997;76(3):306-11. doi: 10.1038/bjc.1997.383. Br J Cancer. 1997. PMID: 9252196 Free PMC article.

7

Tumor-associated proteolytic factors uPA and PAI-1 in endometrial carcinoma.

Köhler U, Hiller K, Martin R, Langanke D, Naumann G, Bilek K, Jänicke F, Schmitt M. Köhler U, et al. Among authors: janicke f. Gynecol Oncol. 1997 Aug;66(2):268-74. doi: 10.1006/gyno.1997.4751. Gynecol Oncol. 1997. PMID: 9264575

8

Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L.

Thomssen C, Oppelt P, Jänicke F, Ulm K, Harbeck N, Höfler H, Kuhn W, Graeff H, Schmitt M. Thomssen C, et al. Among authors: janicke f. Anticancer Res. 1998 May-Jun;18(3C):2173-80. Anticancer Res. 1998. PMID: 9703780

9

Prognostic impact of tumor biological factors on survival in node-negative breast cancer.

Harbeck N, Dettmar P, Thomssen C, Henselmann B, Kuhn W, Ulm K, Jänicke F, Höfler H, Graeff H, Schmitt M. Harbeck N, et al. Among authors: janicke f. Anticancer Res. 1998 May-Jun;18(3C):2187-97. Anticancer Res. 1998. PMID: 9703782

10

Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.

Kuhn W, Schmalfeldt B, Reuning U, Pache L, Berger U, Ulm K, Harbeck N, Späthe K, Dettmar P, Höfler H, Jänicke F, Schmitt M, Graeff H. Kuhn W, et al. Among authors: janicke f. Br J Cancer. 1999 Apr;79(11-12):1746-51. doi: 10.1038/sj.bjc.6690278. Br J Cancer. 1999. PMID: 10206287 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

193 results

Search Page